James Neal Buys Shares of Processa Pharmaceuticals

James Neal made a move in the stock market by purchasing 203 shares of Processa Pharmaceuticals, Inc. on June 26, 2026. This insider transaction did not have a planned schedule and was executed without a disclosed price or total value.

Insider Buying and Selling at Processa Pharmaceuticals, Inc.

On June 26, 2026, several insiders were active at Processa Pharmaceuticals. James Neal bought 203 shares, while other insiders, such as Justin Yorke and Khoso Baluch, also added 203 shares each to their holdings. These transactions were not part of any prearranged trading plans.

Other Institutional Activity in Processa Pharmaceuticals

CONNECTIVE CAPITAL MANAGEMENT, LLC opened a new position in Processa Pharmaceuticals, holding 70,736 shares valued at about $178,608. STONEPINE CAPITAL MANAGEMENT, LLC significantly increased its stake by 42,677 shares, ending with 55,000 shares worth roughly $138,875, marking a 346.3% increase. GEODE CAPITAL MANAGEMENT, LLC also grew its holdings by 9,585 shares to a total of 24,908 shares valued at approximately $62,768, a 62.6% increase. Meanwhile, UBS GROUP AG reduced its position by 10,109 shares, holding 2,531 shares valued at $6,391, reflecting an 80% decrease.

Processa Pharmaceuticals, Inc. Stock Down 6.3%

Shares of NasdaqCM:PCSA traded near $1.92 on Wednesday. The company has a market capitalization of about $5.1 million and a forward P/E ratio that isn't meaningful due to a lack of profitability. The stock's beta is 0.961, indicating moderate volatility. Over the past year, the stock has seen a low of $1.76 and a high of $14.25. The 50-day moving average stands at $2.56, while the 200-day moving average is $4.23. Processa's current ratio is 0.979, with a quick ratio of 0.854.

Analysts Set New Price Targets

On September 2, 2025, HC Wainwright & Co. maintained its 'buy' rating for Processa Pharmaceuticals with a $1.00 price target. Previously, on June 30, 2025, the firm had also maintained a 'buy' rating with a $2.00 target. Maxim Group, on May 19, 2023, maintained its 'buy' rating with a $2.00 target.

About Processa Pharmaceuticals

Processa Pharmaceuticals, Inc., based in Vero Beach, Florida, is a clinical-stage biopharmaceutical company focused on developing cancer therapy drugs. These drugs aim to enhance the safety and effectiveness of cancer treatment by modifying existing FDA-approved oncology drugs. The company's pipeline includes NGC-Cap (PCS6422) in Phase 2 trials for various solid tumors and NGC-Iri (PCS11T) in preclinical trials for several cancers. Additionally, Processa develops non-oncology drugs, including PCS499 for primary glomerular diseases and PCS12852 for gastroparesis and constipation disorders. Founded in 2015, the company employs 12 people and is led by CEO George K. Ng.

Bottom Line

James Neal's purchase of shares in Processa Pharmaceuticals highlights ongoing insider interest in the company. Investors often track insider transactions for potential signals about a company's prospects. However, it's important to remember that such filings are backward-looking and may not reflect current holdings.